WuXi Advanced Therapies Inc. (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, opened its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia. The new facility is the company’s fourth manufacturing site worldwide and will supplement sites in the U.S., UK and China with enhanced capacity and services.
 
The Lin-gang facility offers integrated development, manufacturing, and testing services for viral vectors and cell therapies. It contains more than 200 independent suites and six complete production lines, including an independent liquid distribution center and independent GMP standard sterile filling isolator. These resources will strengthen operations worldwide in the delivery of viral vectors and cell therapies.
 
The Lin-gang facility’s opening follows a major expansion of WuXi ATU’s Philadelphia Navy Yard campus in 2020 that tripled its advanced testing capacity and provided much needed services for clients globally.
 
“Cell and gene therapies play a critical role in helping treat and prevent many severe and rare diseases, which is why WuXi ATU is committed to growing our comprehensive one-stop service platform specifically dedicated to the gene and cell therapy field,” said Dr. David Chang, Chief Executive Officer of WuXi ATU. “By expanding our global footprint, we will provide enhanced cell and gene therapy manufacturing services for our customers worldwide and better enable them to deliver more effective and accessible advanced therapies to patients.”